Cellect Biotechnology Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Cellect Biotechnology Ltd. (a foreign private issuer) on September 8, 2017, regarding events occurring on September 7, 2017. The filing discloses a registered direct offering of American Depositary Shares (ADSs) to certain accredited investors.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $4.3 million.
- Shares Issued: 531,136 ADSs.
- Purchase Price: $8.10 per ADS.
- Warrants Issued: 265,568 unregistered warrants (50% of shares sold).
- Warrant Terms: Exercise price of $12.07 per ADS; 12-month term; exercisable immediately; cashless exercise option available if no effective registration statement exists.
- Placement Agent Fees: 7% cash fee of aggregate purchase price, plus a $15,000 non-accountable expense allowance and up to $30,000 for certain expenses.
- Placement Agent Warrants: Warrants equal to 5% of ADSs placed, with an exercise price of $10.125 per ADS.
Material Changes
The filing does not provide comparative financial data (revenue, profit, cash flow, or margins) for the current period versus prior periods. The primary material change is the capital raise transaction described above, which is expected to close on or about September 11, 2017, subject to customary closing conditions.
Outlook, Risks, and Contingencies
- Closing Contingency: The offering is subject to satisfaction of customary closing conditions; failure to meet these conditions may prevent the offering from closing.
- Forward-Looking Statements: The filing includes a warning that statements regarding the expected closing date are not guaranteed and may not occur due to reasons beyond the Company's control.
- Regulatory Status: Warrants and underlying ADSs are sold pursuant to exemptions from registration (Section 4(a)(2) of the Securities Act and Rule 506/Regulation S) and are not registered under the Securities Act of 1933.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected September 11, 2017) and confirmation of gross proceeds received.
- Review the definitive Securities Purchase Agreement (Exhibit 10.1) and Warrant Agreement (Exhibit 10.2) for specific covenants and adjustment mechanisms.
- Confirm the use of proceeds, as the filing does not explicitly state the intended allocation of the $4.3 million.
- Monitor subsequent filings for any dilution impact from the exercise of the 265,568 investor warrants and placement agent warrants.